Results 41 to 50 of about 1,853,915 (311)

Advances in immunotherapy for hepatocellular carcinoma

Nature reviews: Gastroenterology & hepatology, 2021
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs ...
B. Sangro, P. Sarobe, S. Hervás-Stubbs, I. Melero   +3 more
semanticscholar   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W, Faltermeier, Claire, Zarrinpar, Ali   +2 more
core   +2 more sources

Spatially resolved visualization of reprogrammed metabolism in hepatocellular carcinoma by mass spectrometry imaging

Cancer Cell International, 2023
Background Metabolic reprogramming refers to tumor-associated metabolic alterations during tumorigenesis and has been regarded as one of the most important features of cancer.
Bangzhen Ma, Yang Zhang, Jiwei Ma, Xinguo Chen, Chenglong Sun, Chengkun Qin   +5 more
doaj   +1 more source

Prevention of hepatocellular carcinoma [PDF]

Annals of Hepatology, 2005
Because of its frequency and grave prognosis, preventing hepatocellular carcinoma is an urgent priority. Prevention should be possible because environmental carcinogens-chronic hepatitis B and C virus infections, dietary exposure to aflatoxins, and iron overload-cause the great majority of these tumors.
openaire   +9 more sources

miR-100 Suppresses the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma Cells via Targeting CXCR7

Journal of Immunology Research, 2021
This study is to elucidate the functions of miR-100 in hepatocellular carcinoma progression and to explore the underlying mechanisms. Expression levels of miR-100 in normal-cancer hepatocellular carcinoma tissues were measured using quantitative real ...
Yiman Ge, Jia Shu, Gang Shi, Fuguo Yan, Yejing Li, Hangliang Ding   +5 more
doaj   +1 more source

Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma [PDF]

, 2007
Background/ Aims: To evaluate the long-term outcome of surgical and non-surgical local treatments of patients with hepatocellular carcinoma (HCC). Methods: We stratified a cohort of 278 HCC patients using six independent predictors of survival according ...
Angelika Schrader, Bloomston M, Bosch FX, Burkhard Göke, Castells A, Christian Graeb, Christoph Jüngst, Curley SA, Dieter Jüngst, Florian Löhe, Franco D, Goldberg SN, Gundula Straub, Horst-Günter Rau, Karl-Walter Jauch, Kotoh K, Livraghi T, Livraghi T, Livraghi T, Maximilian Reiser, Qian J, Ralf-Thorsten Hoffmann, Rolf Schauer, Rossi S, Rossi S, Ryder SD, Sasaki Y, Selin Dogan, Takenaka K, Thomas Helmberger, Tobias Jakobs, Tobias Waggershauser, Wolfgang H. Caselmann   +32 more
core   +1 more source

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment [PDF]

, 2014
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third leading cause of cancer deaths. microRNAs (miRNAs) are evolutionary conserved small non-coding RNA that negatively regulate gene expression and protein translation ...
Bianconi Maristella, Cascinu Stefano, D'Anzeo Marco, Del Prete Michela, Faloppi Luca, Giampieri Riccardo, SCARTOZZI, MARIO, Silvestris Nicola   +7 more
core   +1 more source

Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy

Technology in Cancer Research & Treatment, 2020
Background: Cancer-testis genes can serve as prognostic biomarkers and valuable targets for immunotherapy in multiple tumors because of their restricted expression in testis and cancer.
Yan-Peng Zhang MD, Zhi-Wei Bao PhD, Jing-Bang Wu PhD, Yun-Hao Chen PhD, Jun-Ru Chen PhD, Hai-Yang Xie PhD, Lin Zhou PhD, Jian Wu PhD, Shu-Sen Zheng PhD   +8 more
doaj   +1 more source

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Clinical Oncology, 2020
PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC).
R. Finn, M. Ikeda, A. Zhu, M. Sung, A. Baron, M. Kudo, T. Okusaka, M. Kobayashi, H. Kumada, S. Kaneko, M. Pracht, K. Mamontov, T. Meyer, T. Kubota, C. Dutcus, Kenichi Saito, A. Siegel, L. Dubrovsky, K. Mody, J. Llovet   +19 more
semanticscholar   +1 more source

Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE) : study protocol for a randomized controlled trial [PDF]

, 2012
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such ...
Al Younis, Imad, Coenraad, Minneke J, Defreyne, Luc, Lam, Marnix GEH, Lambert, Bieke, Seinstra, Beatrijs A, van den Bosch, Maurice AAJ, van Erkel, Arian R, van Erpecum, Karel J, van Hoek, Bart, Van Vlierberghe, Hans, Verkooijen, Helena M   +11 more
core   +1 more source